242 publications
Name | Date | Type | Actions |
---|---|---|---|
2024 half-year Results Sales: €264m (+3.2% as reported) |
Public releases | ||
2024 Half-Year Results slideshow Contents |
Half Year Report | ||
Rapport financier semestriel 2024 (French) Rapport financier semestriel 2024 (French) |
Half Year Report | ||
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
Public releases | ||
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
Public releases | ||
Universal registration document 2023 XBRL version Universal Registration Document including the Annual Financial Report |
Reference document | ||
Universal registration document 2023 Universal Registration Document including the Annual Financial Report |
Reference document | ||
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
Public releases | ||
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
Public releases | ||
Sales 3rd quarter 2023: 136M€ The Vetoquinol Group posted sales of €136 million in Q3 2023, up +1.3% on a reported basis and +5.1% at constant exchange rates. Over the same period, Vetoquinol recorded a negative currency impact of -€5 million, linked to the Americas and Asia Pacific/Rest of World territories. |
Public releases |